Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling

Oncogene

Volumn 26, Issue 50, 2007, Pages 7132-7142

  Lackey, J ^a   Barnett, J ^a   Davidson, L ^a   Batty, I H ^a   Leslie, N R ^a   Downes, C P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Feedback; Insulin like growth factor; Phosphatase; Phosphoinositide; Signal transduction; Tumor suppressor

Indexed keywords

BETA ACTIN; EPIDERMAL GROWTH FACTOR; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL TYPE; CONTROLLED STUDY; DESENSITIZATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE; CELL LINE, TUMOR; DOGS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MICE; NIH 3T3 CELLS; PHOSPHATIDYLINOSITOL PHOSPHATES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 35848955229     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210520     Document Type: Article

References (40)

1. Batty IH, Fleming IN, Downes CP. (2004). Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells. Biochem J 379: 641-651.
2. Board R, Jayson GC. (2005). Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 8: 75-83.
3. Cheung PC, Campbell DG, Nebreda AR, Cohen P. (2003). Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 22: 5793-5805.
4. Cully M, You H, Levine AJ, Mak TW. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192.
5. Cutillas PR, Khwaja A, Graupera M, Pearce W, Gharbi S, Waterfield M et al. (2006). Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc Natl Acad Sci USA 103: 8959-8964.
6. Danilkovitch-Miagkova A, Zbar B. (2002). Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109: 863-867.
7. Darragh J, Soloaga A, Beardmore VA, Wingate AD, Wiggin GR, Peggie M et al. (2005). MSKs are required for the transcription of the nuclear orphan receptors Nur77, Nurr1 and Nor1 downstream of MAPK signalling. Biochem J 390: 749-759.
8. Fisher TL, White MF. (2004). Signaling pathways: the benefits of good communication. Curr Biol 14: R1005-R1007.
9. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E et al. (2006). Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441: 366-370.
10. Harrington LS, Findlay GM, Lamb RF. (2005). Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30: 35-42.
11. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223.
12. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. (2002). Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62: 2942-2950.
13. Jackson JG, Yee D. (1999). IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. Growth Horm IGF Res 9: 280-289.
14. Javelaud D, Mauviel A. (2005). Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24: 5742-5750.
15. Keeton AB, Bortoff KD, Franklin JL, Messina JL. (2005). Blockade of rapid versus prolonged extracellularly regulated kinase 1/2 activation has differential effects on insulin-induced gene expression. Endocrinology 146: 2716-2725.
16. Kiepe D, Ciarmatori S, Hoeflich A, Wolf E, Tonshoff B. (2005). Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFBP)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways. Endocrinology 146: 3096-3104.
17. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733-747.
18. Lam K, Carpenter CL, Ruderman NB, Friel JC, Kelly KL. (1994). The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J Biol Chem 269: 20648-20652.
19. LeRoith D, Roberts Jr CT. (2003). The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137.
20. Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP. (2001). Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J 357: 427-435.
21. Liu YF, Paz K, Herschkovitz A, Alt A, Tennenbaum T, Sampson SR et al. (2001). Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 276: 14459-14465.
22. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C et al. (2005). A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8: 111-118.
23. Mise-Omata S, Obata Y, Iwase S, Mise N, Doi TS. (2005). Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells. Biochem Biophys Res Commun 328: 1034-1042.
24. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. (2004). Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230.
25. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. (1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513-13518.
26. Natarajan M, Lin KM, Hsueh RC, Sternweis PC, Ranganathan R. (2006). A global analysis of cross-talk in a mammalian cellular signalling network. Nat Cell Biol 8: 571-580.
27. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
28. Parrizas M, Saltiel AR, LeRoith D. (1997). Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272: 154-161.
29. Pirola L, Johnston AM, Van Obberghen E. (2004). Modulation of insulin action. Diabetologia 47: 170-184.
30. Ravichandran LV, Esposito DL, Chen J, Quon MJ. (2001). Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. J Biol Chem 276: 3543-3549.
31. Sajan MP, Standaert ML, Bandyopadhyay G, Quon MJ, Burke Jr TR, Farese RV. (1999). Protein kinase C-zeta and phosphoinositide-dependent protein kinase-1 are required for insulin-induced activation of ERK in rat adipocytes. J Biol Chem 274: 30495-30500.
32. Shaw RJ, Cantley LC. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
33. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M et al. (2005). The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets 9: 1009-1030.
34. Simpson L, Li J, Liaw D, Hennessy I, Oliner J, Christians F et al. (2001). PTEN expression causes feedback upregulation of insulin receptor substrate 2. Mol Cell Biol 21: 3947-3958.
35. Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R et al. (2002). Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 22: 3842-3851.
36. Stocker H, Andjelkovic M, Oldham S, Laffargue M, Wymann MP, Hemmings BA et al. (2002). Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295: 2088-2091.
37. Um SH, D'Alessio D, Thomas G. (2006). Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 3: 393-402.
38. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M et al. (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200-205.
39. Vivekanand P, Rebay I. (2006). Intersection of signal transduction pathways and development. Annu Rev Genet 40: 139-157.
40. White MF. (2002). IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413-E422.